Quantcast

Latest Genentech Stories

2014-04-02 12:32:34

NEW YORK, April 2, 2014 /PRNewswire-iReach/ -- A mobile application focusing on rheumatoid arthritis management -- created by DKBmed, LLC, in collaboration with Clifton O. Bingham III, MD, Director of the Johns Hopkins Arthritis Center and the Johns Hopkins University School of Medicine -- was ranked #1 in 2013 by rheumatologists on the Rheumatology Network website and highly rated in 2014 on the Healthline website. Called Rheumatoid Arthritis Vital Education (RAVE) Mobile, the app was...

2014-03-27 12:31:03

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Monoclonal Antibody Industry Report, 2013-2017 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...

2014-03-27 12:30:38

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rwdz5w/therapy_class ) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade,...

2014-03-26 08:28:26

VANCOUVER, British Columbia, March 26, 2014 /PRNewswire/ -- Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon's Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive...

2014-03-25 20:22:11

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and ) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report" [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Currently, monoclonal antibody agents have been successfully used in the treatment...

2014-03-25 12:29:41

Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014 /PRNewswire/ -- Decision Resources Group finds that efficacy more than any other factors drives oncologists' prescribing of targeted therapies for breast cancer and, according to the majority of surveyed oncologists, the escalating overall cost of drug treatment for breast cancer has little or no impact...

2014-03-25 00:23:20

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" [http://www.researchandmarkets.com/research/llq9cw/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to...

2014-03-24 20:22:55

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation Report on China Trastuzumab Market, 2009-2018" [http://www.researchandmarkets.com/research/czqbv2/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main...

2014-03-24 12:30:49

LONDON, March 24, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Analysis of the US Retinal Therapeutics Market Improvements in Administration and Efficacy Drive GrowthSince the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research...

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'